Literature DB >> 26711786

Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer.

Xiaozhen Liu1, Changyun Feng2, Junjun Liu1, Lin Zhao1, Jian Liu1, Wei Zhang1, Ning Liu3, Yun Niu4.   

Abstract

Molecular apocrine breast cancer (MABC) has a distinct hormonal profile, being estrogen receptor (ER) and progesterone receptor (PR) negative but androgen receptor (AR) positive. The clinical significance of MABC and its relative variables have not been absolutely clarified and remain to be determined. Five hundred cases of invasive breast carcinoma were randomly selected in this study, including 158 MABC cases and 342 nonMABC cases. Expression of ER, PR, epidermal growth factor receptor 2 (HER2), Ki67, AR, gross cystic disease fluid protein 15 (GCDFP15), and heat shock protein 27 (HSP27) were analyzed by immunohistochemistry. Differences of continuous variables between MABC and nonMABC subgroups were evaluated by the chi-square test. The Kaplan-Meier method was performed to evaluate disease-free survival (DFS) and overall survival (OS). The MABC subgroup had higher histological grade, bigger tumor size, more lymph node metastasis, and higher pTNM stage than the nonMABC subgroup (P < 0.05), and patients with MABC had poorer prognosis than those of the nonMABC subgroup (P < 0.05). Both GCDFP15 and HSP27 were expressed differently in the MABC and nonMABC subgroups (P < 0.05). Furthermore, in the MABC subgroup, positive HSP27 expression indicated higher risk of recurrence (P < 0.05) and positive GCDFP15 expression was also a poor marker for patient outcome (P < 0.05). MABC patients with HSP27 and GCDFP15 co-expression had worse outcome (P < 0.05). Our data suggested that MABC had a high risk of recurrence. Positive expression of both GCDFP15 and HSP27 were correlated with MABC malignancy. Targeting AR and HSP27 at the same time might offer a useful strategy to MABC.

Entities:  

Keywords:  Androgen receptor; Breast cancer; Gross cystic disease fluid protein 15; Heat shock protein 27; Molecular apocrine subgroup

Mesh:

Substances:

Year:  2015        PMID: 26711786     DOI: 10.1007/s13277-015-4712-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  33 in total

1.  Effect of the heat shock protein HSP27 on androgen receptor expression and function in prostate cancer cells.

Authors:  Matthias B Stope; Tina Schubert; Doreen Staar; Cindy Rönnau; Andreas Streitbörger; Nils Kroeger; Constanze Kubisch; Uwe Zimmermann; Reinhard Walther; Martin Burchardt
Journal:  World J Urol       Date:  2012-02-24       Impact factor: 4.226

Review 2.  Role of the androgen receptor in human breast cancer.

Authors:  S N Birrell; R E Hall; W D Tilley
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

3.  Expression of androgen receptor in breast cancer and its significance as a prognostic factor.

Authors:  Q Yu; Y Niu; N Liu; J Z Zhang; T J Liu; R J Zhang; S L Wang; X M Ding; X Q Xiao
Journal:  Ann Oncol       Date:  2010-11-25       Impact factor: 32.976

4.  Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity.

Authors:  Amina Zoubeidi; Anousheh Zardan; Eliana Beraldi; Ladan Fazli; Richard Sowery; Paul Rennie; Colleen Nelson; Martin Gleave
Journal:  Cancer Res       Date:  2007-11-01       Impact factor: 12.701

5.  Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.

Authors:  Amelia A Peters; Grant Buchanan; Carmela Ricciardelli; Tina Bianco-Miotto; Margaret M Centenera; Jonathan M Harris; Shalini Jindal; Davendra Segara; Li Jia; Nicole L Moore; Susan M Henshall; Stephen N Birrell; Gerhard A Coetzee; Robert L Sutherland; Lisa M Butler; Wayne D Tilley
Journal:  Cancer Res       Date:  2009-07-28       Impact factor: 12.701

6.  Supervised risk predictor of breast cancer based on intrinsic subtypes.

Authors:  Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

7.  Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy.

Authors:  L M Vargas-Roig; F E Gago; O Tello; J C Aznar; D R Ciocca
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

8.  Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.

Authors:  Li Wei; Tsung-Ta Liu; Hsiu-Huan Wang; Hui-Mei Hong; Alice L Yu; Hsiang-Pu Feng; Wen-Wei Chang
Journal:  Breast Cancer Res       Date:  2011-10-24       Impact factor: 6.466

9.  Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors.

Authors:  Luis O Gonzalez; Maria D Corte; Julio Vazquez; Sara Junquera; Rosario Sanchez; Ana C Alvarez; Juan C Rodriguez; Maria L Lamelas; Francisco J Vizoso
Journal:  BMC Cancer       Date:  2008-05-28       Impact factor: 4.430

10.  Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family.

Authors:  Sandeep Sanga; Bradley M Broom; Vittorio Cristini; Mary E Edgerton
Journal:  BMC Med Genomics       Date:  2009-09-11       Impact factor: 3.063

View more
  1 in total

1.  Early versus late distant metastasis and adjuvant chemotherapy alone versus both radiotherapy and chemotherapy in molecular apocrine breast cancer.

Authors:  Xiaozhen Liu; Yang Yang; Xiaolong Feng; Honghong Shen; Jian Liu; Xia Liu; Yun Niu
Journal:  Oncotarget       Date:  2016-08-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.